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A comparison of endoscopy versus pathology sizing of colorectal 
adenomas and potential implications for surveillance colonoscopy 
ABSTRACT 
Background and Aims: To compare endoscopy and pathology sizing in a large 
population-based series of colorectal adenomas and to evaluate the implications for 
patient stratification into surveillance colonoscopy.  
 
Methods: Endoscopy and pathology sizes available from intact adenomas removed at 
colonoscopies performed as part of the Northern Ireland Bowel Cancer Screening 
Programme, from 2010 to 2015, were included in this study. Chi-squared tests were 
applied to compare size categories in relation to clinicopathological parameters and 
colonoscopy surveillance strata according to current American Gastroenterology 
Association and British Society of Gastroenterology guidelines. 
 
Results: A total of 2521 adenomas from 1467 individuals were included. There was a 
trend toward larger endoscopy than pathology sizing in 4 of the 5 study centers, but 
overall sizing concordance was good. Significantly greater clustering with sizing to the 
nearest 5 mm was evident in endoscopy versus pathology sizing (30% vs 19%, p<0.001), 
which may result in lower accuracy. Applying a 10-mm cut-off relevant to guidelines on 
risk stratification, 7.3% of all adenomas and 28.3% of those 8 to 12 mm in size had 
discordant endoscopy and pathology size categorization. Depending upon which 
guidelines are applied, 4.8% to 9.1% of individuals had differing risk stratification for 
surveillance recommendations, with the use of pathology sizing resulting in marginally 
fewer recommended surveillance colonoscopies.  
 
Conclusions: Choice of pathology or endoscopy approaches to determine adenoma size 
will potentially influence surveillance colonoscopy follow-up in 4.8% to 9.1% of 
individuals.  Pathology sizing appears more accurate than endoscopy sizing, and 
preferential use of pathology size would result in a small, but clinically important, 
decreased burden on surveillance colonoscopy demand. Careful endoscopy sizing is 
required for adenomas removed piecemeal. 
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INTRODUCTION 
Adenomatous polyps are well-recognized precursors of colorectal cancer (CRC).
 1
 The 
removal of colorectal adenomas has been shown to both reduce the incidence of, and 
prevent mortality from, CRC.
 2, 3
 Screening for CRC reduces deaths both by detecting 
early cancers at a treatable stage, and by detecting and removing adenomatous polyps, 
the latter being a much more common neoplastic finding at colonoscopy.
 4
 Post-
polypectomy colonoscopic surveillance is required but it is important to enter patients 
into an appropriate surveillance regimen that will optimize their reduction in CRC risk 
and mortality, without overburdening healthcare services.  
BACKGROUND 
There is agreement that the need for surveillance colonoscopy and suggested intervals 
should be determined by the findings at initial colonoscopy. In 2002, and updated in 
2010, the British Society of Gastroenterology (BSG) and the Association of 
Coloproctology for Great Britain and Ireland (ACPGBI) published guidelines for 
surveillance after colorectal adenoma removal. These suggest stratification of 
individuals into low, intermediate and high risk based on the number and size of 
adenomas detected at baseline colonoscopy.
 5, 6
 A cut-off adenoma size of ≥10mm is 
specified. In 2006, the United States Multi-Society Task Force on CRC published broadly 
similar guidelines on post-polypectomy surveillance, updating previous versions.
 7
 These 
guidelines distinguish, for stratification purposes into low or high risk, those individuals 
with 3 or more adenomas, or any adenoma ≥10 mm in size, with villous features on 
histology or with high-grade dysplasia (so-called “advanced adenoma”) from those with 
1 or 2 adenomas <10 mm in size. These guidelines have been endorsed and updated by 
the American Gastroenterology Association (AGA) in 2012.
 8
 
Surprisingly, none of these guidelines offer any detail on how to measure adenoma size, 
and specifically whether to use endoscopy or pathology size in recording baseline 
colonoscopy findings. The reason for this is likely that the cited publications which 
provide the evidence base for these guidelines variably use endoscopy or pathology size, 
and most lack any further detail on how size was derived (Table 1). 
 2, 9-41
 Recent 
guidelines related to CRC screening and management of malignant colorectal polyps 
have advocated use of pathology size over endoscopy, stating that pathology size is 
auditable, accurate, simple to perform, and offers the ability to measure the 
adenomatous component of mixed lesions. 
 42, 43
 There is some evidence to support 
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these conclusions but the relevant studies are mostly based on single-center experience 
and mostly involve small study numbers, ranging from 31 to 235 adenomas.
 44-50
 As such, 
the evidence base for making recommendations on sizing is limited, and requires 
expansion. 
The aim of this large, multicenter study was to compare the endoscopic and pathological 
sizes recorded for colorectal adenomas removed intact during colonoscopy performed 
in the setting of a national CRC screening program, in order to identify and quantify 
factors associated with discordant sizing, to assess the potential impact of discordant 
adenoma sizing on colonoscopy surveillance and to inform future recommendations for 
most accurate sizing of adenomas.   
METHODS 
Northern Ireland Bowel Cancer Screening Program  
The Northern Ireland Bowel Cancer Screening (BCS) Programme was introduced in April 
2010, providing complete coverage of the Northern Ireland population (1.8 million) by 
2012. Initially, 2 yearly fecal-occult blood (FOB) detection kits were offered to those 
individuals aged 60 to 69 years, with subsequent extensions to age 71 years in April 
2012 and to age 74 years in April 2014.  FOB-positive individuals are offered 
colonoscopy. BCS colonoscopies are performed in 5 BCS endoscopy centers, each of 
which has been inspected and approved by the U.K. Joint Advisory Group on endoscopy. 
Endoscopists performing BCS colonoscopy have undergone formal peer assessment 
based on personal colonoscopy quality assurance performance and direct observation of 
procedures. 
Four Northern Ireland histopathology laboratories process BCS specimens from the 5 
BCS endoscopy centers following an agreed protocol for handling and reporting 
polypectomy specimens. This protocol includes general instruction on dissecting 
polypectomy specimens and highlights the importance of accurate sizing of adenomas 
but, similar to guidance offered in the vast majority of histopathology laboratories, does 
not offer any more specific instruction on how to do so. Typically, macroscopic 
assessment in the laboratory provides a 3-dimensional measurement of intact 
polypectomy specimens and any stalk included is measured separately. Microscopy will 
indicate the maximum dimension of the adenomatous component of any such 
specimen, and exclude any non-adenomatous glandular epithelium within surrounding 
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flat mucosa or stalk.  The World Health Organization definitions of adenoma subtypes 
are adhered to, tubulovillous adenoma designation requiring >25% villous architecture 
and villous adenoma designation requiring >75% villous architecture.
 51
 
From the inception of the program, detailed histopathology data has been collected 
centrally on all specimens submitted for histology, including a record of endoscopy and 
pathology sizes for all adenomas when available.   
Case selection 
Within the Northern Ireland BCS Programme, n=10,008 histopathological specimens 
from n = 4256 colonoscopy episodes have been processed since inception in 2010 up to 
the end of March 2015. Of the n = 10,008 BCS specimens, the following diagnoses were 
excluded from further data analysis for this study: cancers (including “malignant 
polyps”) and specimens diagnosed as suspicious for malignancy (n=402), normal 
(n=489), inflammation (n=407), inflammatory polyp (n=66), benign lymphoid polyp 
(n=13), hyperplastic polyp (n=1530), sessile serrated polyp/adenoma/lesion (n=291), 
traditional serrated adenoma (n=30), or “other diagnosis” (n=213).  This left n=6567 
tubular, tubulovillous, or villous adenomas. Of these, n=2532 had both endoscopy and 
pathology sizes recorded, with piecemeal resection and absent or imprecise (eg, <10 
mm) endoscopy size accounting for the vast majority of excluded adenomas (Fig. 1). A 
number of approaches were then taken to maximize the accuracy of sizing data 
recording within the polyp database for adenomas with recorded endoscopy and 
pathology size.  The majority of these sizings were verified as correct. However, n=10 
were amended to the correct values and n=11 were excluded due to being piecemeal 
resections with pathology sizes inappropriately recorded. After applying these rules, 
n=2521 (38%) adenomas from n=1467 individuals had both endoscopy and pathology 
sizes recorded and these were retained for inclusion in the statistical analysis. The case 
selection process is summarized in Figure 1.   
Statistical analysis 
Differences in median endoscopy and pathology sizes for adenomas were evaluated by 
applying the Wilcoxon signed-rank test of medians.  A Bland-Altman plot was created to 
compare agreement by plotting the size difference (endoscopy minus pathology size) 
against the average of endoscopy and pathology sizes for each adenoma.  Size 
difference was normally distributed. Histograms were generated to compare clustering 
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within endoscopy and pathology sizing, and the proportion of adenomas sized at 5 mm 
increments (in the 0-50 mm range) compared using a chi-squared test.  The number of 
adenomas sized at 5-mm intervals is an indicator of probable rounding up or down of 
sizes, implying a less-accurate approach to measurement. Adenoma sizes were then 
categorized according to usual strata for surveillance, ie, < or ≥10 mm, for purposes of 
comparison.  The association between discordant size classification (endoscopy versus 
pathology) and other factors was evaluated by chi-squared tests to determine any 
predictors of discordance, including endoscopy center, pathology laboratory, sex, and 
adenoma location.     
Data were collapsed to evaluate strata based on these size cut-offs for individuals 
(colonoscopy episodes), also taking into consideration multiplicity, villousness, and high-
grade dysplasia to reflect AGA surveillance interval categorization and multiplicity to 
reflect BSG criteria. Individuals with a concurrent cancer (or suspicious for malignancy) 
diagnosis in any lesion removed were excluded from this analysis (n=67), leaving n=1400 
for subsequent analysis. When individuals had multiple adenomas, the priority for 
classification was (1) agreed large size (≥10 mm), (2) endoscopy size large but pathology 
size small (10 mm cut-off), (3) endoscopy size small but pathology size large (10 mm cut-
off) and, finally, and (4) agreed small size (<10 mm). 
RESULTS  
Table 2 compares endoscopic and pathological sizing for all n=2521 adenomas with 
available size data, of which 73% were tubular adenomas and 27% had a villous 
component.  Adenomas with a villous component were typically larger than tubular 
adenomas, median sizes 12 mm and 4 mm, respectively. No significant differences in 
median values were observed between endoscopy and pathology size for tubular or 
tubulovillous/villous adenomas. A visual representation of the agreement between 
endoscopic and pathological sizing for all adenomas is shown in Figure 2.  This shows 
good overall agreement, with a mean size difference of 0.1 mm (95% limits of 
agreement, -4.45 to 4.65 mm) and with a tendency for endoscopy sizing to be greater 
than pathology sizing as adenoma size increases. 
Figure 3 illustrates the frequencies for the spectrum of recorded adenoma sizes by 
endoscopy and pathology.  Clustering at 5-mm increments was more visible for 
endoscopy than pathology sizing, evident by clearly more prominent peaks at 5, 10, 15, 
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and 20 mm. Similarly, when evaluating the proportion of adenomas sized at 5-mm 
intervals in the entire 0 to 50 mm range, significantly greater clustering was evident for 
endoscopy versus pathology sizing (30% versus 19%, p<0.001). 
The proportions of adenomas classified as small or large according to AGA/BSG criteria 
(<10mm versus ≥10 mm) are shown in Table 3.  Overall, agreement of endoscopy and 
pathology size classification using this 10mm cut-off was very high (92.7%).  Of 
adenomas with discordant sizes, similar proportions were classified as small based on 
endoscopy size, but large on pathology size (3.1%), and vice versa (4.2%).  Discordant 
stratification was more evident for tubulovillous than tubular adenomas (p<0.001), likely 
reflecting the larger median size of tubulovillous adenomas. The proportion of 
adenomas with discordant sizing was much higher when restricting analysis to those in 
the 8 to 12 mm size range, with 28.3% of these n=528 adenomas classified differently, 
applying the 10 mm cut-off, according to endoscopy or pathology sizing. 
When investigating other factors that may predict discordant sizing between endoscopy 
and pathology, no significant influence of sex or adenoma location was detected (Table 
4).  However, discordance rate differences between the 5 BCS endoscopy centers were 
significant (range 4.9-10.5%, p<0.001), with all but one endoscopy center trending 
toward adenomas being measured larger on endoscopy compared to pathology.   Of 
note, BCS endoscopy centers A and B reflect 2 separate endoscopy services, but both 
serviced by the same pathology department.  Interestingly, discordance within 
endoscopy center A had a tendency toward greater endoscopy size than pathology size 
(7.9% versus 2.5%), whereas discordance within endoscopy center B had a tendency 
toward greater pathology size than endoscopy size (5.2% versus 2.7%).  
Information was then collapsed to reflect the potential for individuals, rather than 
adenomas, to be classified differently (with accompanying implications for 
recommended surveillance) according to endoscopy or pathology sizing, as shown in 
Table 5.  Similar to analysis by individual adenomas, overall sizing concordance was very 
high (90.4%), with only 9.6% (n=135) of individuals showing discordance between 
endoscopy and pathology sizing of their largest adenoma.  Regarding implications for 
surveillance colonoscopy recommendations, the use of pathology size would potentially 
result in a marginally decreased burden on colonoscopy services compared with using 
endoscopy size (Table 5).  This would lead to 1.1% more individuals stratified into low 
risk compared with high-risk categories according to AGA criteria (60.9 vs 62.0%, 
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respectively).  Similarly, when applying BSG criteria, 2.3% more individuals would be 
stratified as low risk if pathology size is applied rather than endoscopy size (49.9% vs 
47.6%, respectively).   
Once other factors are taken into consideration, the proportion of patients whose entry 
into surveillance would be altered due to discordant endoscopy versus pathology sizing 
is slightly reduced. Using AGA criteria, n=68 of the n=135 individuals with sizing 
discordance would be classified as high risk on the basis of high grade dysplasia and/or 
villousness within their adenomas, and therefore the sizing discordance would not 
influence stratification. The remaining n=67 (4.8%) would be stratified on the basis of 
adenoma sizing and in these individuals the sizing discordance results in differing 
stratification. Similarly, using BSG criteria, n=8 individuals had 5 or more adenomas 
detected and would be stratified into the high-risk group, regardless of which sizing 
modality is applied. The remaining n=127 (9.1%) individuals with sizing discordance and 
fewer than 5 adenomas, will all have risk stratification determined by whichever sizing 
modality is applied, and therefore the potential to be placed into an inappropriate 
surveillance interval.  
DISCUSSION 
Accurately measuring colorectal adenomas is of fundamental importance to post-
polypectomy surveillance strategies, yet limited guidance is available on whether to use 
endoscopy or pathology sizes.
 5-8
 Table 1 highlights the varied approaches to adenoma 
sizing within the existing literature that provides the evidence base for both U.S. and 
U.K. surveillance guidelines. In the largest such study to date, we have compared the 
endoscopic and pathological sizes recorded for 2521 colorectal adenomas removed 
intact during colonoscopy performed in the setting of CRC screening, with the aims of 
identifying and quantifying factors associated with discordant sizing, assessing impact of 
discordant sizing on colonoscopy surveillance and informing future recommendations 
for most accurate sizing of adenomas.  We found that endoscopy and pathology sizes of 
adenomas are broadly comparable but that pathology sizing is likely to be more accurate 
for a variety of reasons and should be used, when available, for clinical decision making. 
Use of pathology rather than endoscopy sizes would place slightly less burden on 
surveillance colonoscopy demand. 
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The study found good overall concordance between endoscopy and pathology sizing of 
colorectal adenomas, despite any specific guidance issued to endoscopists or 
pathologists at the outset, and recognizing a likely wide variety of approaches to sizing, 
especially within endoscopy practice. A total of 7.3% of adenomas had discordant 
endoscopy and pathology sizing with respect to the 10 mm size cut-off, used in the 
major international risk stratification systems.
 5-8
 Within the 8 to 12 mm adenoma size 
range, 28.3% of adenomas had discordant sizing. This much-higher proportion is 
unsurprising when restricting analysis to adenomas straddling the cut-off size but does 
emphasize the need for particular vigilance when assessing adenomas around this size. 
There was a slight tendency overall in this study toward larger endoscopy than 
pathology sizing, with this trend evident in 4 of the 5 endoscopy centers involved. 
Similarly, most previous related studies, although based on small study numbers and 
performed in a variety of clinical settings, typically describe larger endoscopy than 
pathology adenoma sizing.
 45-47
 One very recent, large, study which included 1528 polyps 
(931 adenomas) reported significant endoscopy over-sizing.
 52
 Forty-six percent of 222 
polyps estimated as ≥cm on endoscopy, were <1 cm on pathology, in contrast to only 
3.9% of 1306 polyps estimated as <1 cm on endoscopy, proving to be ≥1 cm on 
pathology. Occasional studies have described smaller endoscopy sizing compared with 
pathology.
 44, 48
 One study, also performed in the BCS setting within the UK, reported no 
significant difference between endoscopy size (in vivo) and pathology size (macroscopic, 
post-fixation).
 50
 
Endoscopy sizing can be performed in vivo or after retrieval once in the specimen 
container.
 48
 In vivo measurement is visual but can be aided by comparison to an open 
pair of snare forceps, the diameter of which is 8 mm. This aid is less useful for adenomas 
much larger than 8 mm. In vivo measurement can be made more difficult if the forceps 
cannot be opened in the same plane as the maximum diameter of the polyp, or if the 
polyp is obscured by a mucosal fold. Many potential reasons to explain larger endoscopy 
than pathology size, relating to both endoscopy and pathology, have been described in 
previous smaller, single-center studies. 
 44-47, 49
 Visual estimation by the endoscopist, 
either in vivo or within the specimen container, may encourage rounding up in size, 
evidenced by clustering at 5-mm increments. Optical instrumentation and camera 
placement during endoscopy may cause distortion of the polyp image and 
overestimation of in vivo measurement. There may be shearing of the adenoma during 
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withdrawal leading to partial reduction in its size. Formalin fixation has also been 
reported to cause shrinkage of the polypectomy specimen. Only part of the polyp may 
be adenomatous microscopically (Fig. 4). Finally, pathology size underestimation may 
result from inappropriate recording of the largest microscopic adenoma diameter, when 
the largest adenoma dimension has not been represented on the glass slide. 
This study provides some evidence to suggest that endoscopy sizing is less accurate than 
pathology sizing. First, significantly greater clustering at 5 mm increments was evident in 
endoscopy versus pathology sizing, implying less accuracy. This has been reported 
previously.
 47, 52
 Several guidelines specifically state that adenoma measurements should 
be accurate to the nearest millimeter and not rounded to the nearest 5 or 10 mm. 
 42, 43
  
Pathology sizing is perhaps more objective and some endoscopists may have a tendency 
to round up in size to err on the side of caution with respect to the surveillance 
colonoscopy interval. 
Second, although there was marked variation in endoscopy/pathology sizing 
discordance between the 5 BCS endoscopy centers (range 4.9%-10.5%, p<0.001) and this 
could be due to either endoscopy or pathology factors (or both), 2 endoscopy centers 
served by the same pathology department demonstrated different trends in 
discordance, one with endoscopy sizes generally larger than pathology and the other 
with pathology sizes generally larger than endoscopy. As it seems highly unlikely that the 
approach to pathology reporting should vary between these 2 centers, this strongly 
suggests different approaches to endoscopy sizing between these 2 centers. 
Many studies have concluded that formalin fixation does not result in significant 
adenoma shrinkage, and so this explanation for sizing discordance can be largely 
discounted. 
 44, 45, 49
 Clearly, polyps that are only partly adenomatous can only be 
accurately assessed microscopically, using a Vernier scale or eyepiece graticule. 
Polypectomy specimens that include a margin of surrounding normal mucosa may be 
difficult to accurately size at endoscopy or at any stage before microscopy. Several 
recent guidelines have made the general recommendation that the microscopic 
pathology size is used because it is considered auditable, simple to perform, and able to 
assess the adenomatous component of mixed lesions. 
 42, 43
 Larger adenomas may be 
most easily measured using a magnified graticule/measuring cylinder. 
 47, 53
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Microscopy allows measurement only of the 2 dimensions represented on the glass 
slide. Therefore, if at polyp dissection, the maximum dimension is not presented, by 
sectioning through the largest polyp axis, microscopic measurement will be an 
underestimate. It is imperative that, during specimen dissection in the pathology 
laboratory post-fixation, every effort is made to represent the largest polyp dimension 
on the glass slide and, furthermore, if this has not been possible, this information is 
conveyed clearly to the reporting pathologist, whose microscopic adenoma 
measurement is then largely meaningless, unless only a portion of the lesion is 
adenomatous. If the whole polyp is adenomatous, it is appropriate to record the fixed 
macroscopic size as the maximum adenoma dimension.  
For most accurate adenoma sizing across a broad range of sizes, we propose that a 
combined approach is required, using endoscopy size for piecemeal resections, post-
formalin fixation macroscopic size for adenomas too large to depict in entirety on glass 
slide and microscopic measurement for small adenomas or polyps with only a partial 
adenomatous component. Careful communication is required between endoscopist, 
dissector and reporting pathologist, to arrive at the most accurate size. Greatest 
attention to endoscopic sizing is required in vivo before a piecemeal resection, at this 
provides the only opportunity for accurate sizing. If endoscopy and pathology sizes are 
available on adenomas removed intact, clinical decision making should be based on the 
pathology size. A suggested algorithm, summarizing this approach to sizing adenomas, is 
depicted in Figure 5.  
Regarding the implications of adenoma sizing on surveillance, our analysis by individual, 
taking into consideration additional stratification criteria as well as adenoma size, 
indicated that use of endoscopy rather than pathology size would place a slightly greater 
burden on colonoscopy resources. More significantly, depending on which sizing 
modality was used, 4.8% and 9.1% of individuals would be placed into different AGA and 
BSG risk categories, respectively, and potentially offered different colonoscopy 
surveillance intervals. A similar conclusion was reached in a recent, large study which 
estimated potentially inappropriate surveillance recommendation in up to 10% of 
individuals with adenomas detected at colonoscopy, if endoscopy sizing was applied.
 52
 
This study however considered only adenoma size in this analysis and did not consider 
adenoma multiplicity, villousness, and dysplasia grade.  
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Another related study involving 15 board-certified gastroenterologists, working in a 
large U.S. academic medical center, demonstrated marked variation in individual 
endoscopist’s ability to accurately size adenomas, assuming pathology size as the 
criterion standard, resulting in a significant impact on colonoscopic surveillance 
recommendations.
 46
 Endoscopic mis-sizing resulted in inappropriate risk stratification in 
35.2% (range 0%-67%) of adenomas, although only adenomas measuring 10 mm or 
more endoscopically were included, limiting comparisons with the current study. Of 
note is the marked variation in endoscopist performance, with some endoscopists 
seemingly able to accurately reproduce pathology sizing. 
 46
 With greater uniformity of 
endoscopy and pathology approaches to adenoma sizing, it is likely that the range of 
discordance could be considerably narrowed, ideally to the point at which any 
differences between endoscopy and pathology sizing are of little clinical significance.  
It should be noted, however, that the current clinically important 1-cm size cut-off is 
based on historical endoscopy, and pathology practice and alternation of either 
methodology should be accompanied by a reappraisal of this threshold for more-intense 
colonoscopic surveillance, based on data relating to current practice.
 54
 More rigorous 
attention to sizing methodology may generate more-robust data relating to implications 
of baseline colonoscopy findings for prediction of future risk of colorectal neoplasia. 
Further stratification of lower risk individuals, who comprised approximately half of all 
patients in our study, may be possible in future modelling work, perhaps according to 
adenomas <5 mm and those 5 to 10 mm in size. It is unlikely someone with 2 adenomas 
measuring 5 to 10 mm is at the same risk of future neoplasia as someone with a single 
adenoma <5 mm in size, both grouped together under current risk stratification systems. 
With high-quality colonoscopy, and more accurate sizing assessment of detected polyps, 
it should be possible to further refine post-polypectomy surveillance, to target resources 
most appropriately, with the potential for healthcare savings should modeling suggest 
some relaxation on current surveillance programs is appropriate.  
This study has a number of strengths, including its large size and population-based 
coverage within an organized national BCS program.  The specimens included reflect 
real-world practice and data, in that endoscopists and pathologists involved would not 
have altered their approaches to adenoma sizing as a result of a study hypothesis. There 
are some limitations to our study. We were only able to include 38% of all adenomas 
removed, due to either pathology or endoscopy size data being unavailable. Piecemeal 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
 
resections and lack of provision of precise endoscopy sizes accounted for a large 
proportion of these. Nevertheless, this is the largest study to date comparing endoscopy 
and pathology adenoma sizing measurements.   An additional limitation is that the 
participants of the BCS program reflect a “high-risk” population who have tested 
positive at FOB testing, and it is possible that our results may not be generalizable to 
adenomas excised from other age groups or non-screening populations.  Similarly, it is 
also unclear whether conclusions from this study can be extrapolated to the non-
screening setting, in which attention to colonoscopy and pathology quality assurance is 
less rigorous.  Finally, the stratification estimates do not take into consideration factors 
such as genetic conditions, family history of cancer and personal history of previous 
adenomas. However it is unlikely that such factors would be impact on pathology and 
endoscopy sizing methods, limiting the impact of such factors on the discrepancies 
reported in this paper.    
In conclusion, this study of a large population-based series of colorectal adenomas 
removed during BCS colonoscopy has shown that although there is overall good 
concordance between endoscopy and pathology adenoma measurement, discordance in 
sizing is a problem, and resulted in a potential change in surveillance stratification for 
4.8% to 9.1% of individuals.  It provides some evidence to suggest that pathology sizing 
of intact adenomas is more accurate than endoscopy sizing, and that preferential use of 
pathology size, where available, would marginally decrease burden on surveillance 
colonoscopy demand.  A combined endoscopy and pathology approach to adenoma 
sizing is proposed, in an effort to maximize accuracy.   
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FIGURE LEGENDS 
Figure 1.  Summary of study case selection process 
Figure 2.  Bland-Altman plot showing agreement between endoscopy and pathology size for n=2521 
colorectal adenomas. 
Figure 3. Histogram of endoscopy and pathology adenoma sizes demonstrating greater clustering at 
5mm and 10mm intervals in endoscopy sizing.  Adenoma size scale restricted to 20mm. 
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Figure 4.  Whole glass slide image depicting a 10mm diameter polypectomy specimen (endoscopy 
size and fixed macroscopic pathology size) which demonstrated a 4mm diameter tubular adenoma 
microscopically, emphasizing the importance of microscopic examination (haematoxylin&eosin). 
Figure 5. Suggested multidisciplinary approach toward most accurate sizing of colorectal adenomas. 
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Table 1 Summary of recommendations for adenoma sizing within all studies providing original data 
cited by United Kingdom 
 5, 6
 and United States 
 7, 8
 guidelines for colonoscopy surveillance after 
adenoma removal (2, 9-41).  
Publication Recommended method of adenoma sizing 
Alberts 2005 Not stated 
Atkin 1992 Pathology (maximum diameter of fixed specimen) 
Avidan 2002 Endoscopy (open biopsy forceps comparison or measured after excision) 
Baron 1999 Endoscopy 
Baron 2003 Endoscopy 
Bertario 2003 Pathology (maximum diameter of fixed specimen) 
Blumberg 2000 Endoscopy 
Bonithon-Kopp 2004 Endoscopy 
Chung 2011 Endoscopy (open biopsy forceps comparison or measured after excision) 
Cottet 2012 Pathology 
Fossi 2001 Endoscopy 
Jorgensen  1995 Endoscopy (measured after excision) 
Laiyemo 2008 Endoscopy 
Lieberman  2007 Endoscopy (open biopsy forceps comparison) 
Martinez 2001 Endoscopy 
Miller J 2010 Endoscopy 
Miller H 2010 Endoscopy 
Noshirwani 2000 Endoscopy 
Nusko 2002 Adenomas ≤5 mm: endoscopy (open biopsy forceps comparison) 
Adenomas >5 mm: pathology 
Schatzkin 2000 Endoscopy 
Stryker 1987 Barium enema 
Van Stolk 1998 Endoscopy 
O’Brien 1990  Endoscopy (open biopsy forceps comparison) 
Yamaji 2004 Endoscopy (open biopsy forceps comparison) 
Yang 1998 Pathology 
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Table 2 Comparison of endoscopic and pathology sizing for all colorectal adenomas.  
  Endoscopy size (mm) Pathology size (mm) P value 
 n (%) Median (IQR) Median (IQR)  
All adenomas 2521 (100)  5 (3-10) 5 (3-10) 0.19 
Tubular adenoma 1835 (73) 4 (3-6) 4 (3-7) 0.33 
Tubulovillous adenoma* 686   (27) 12 (8-15) 12 (9-16) 0.29 
IQR: Inter-quartile range. *Includes n=7 villous adenomas. 
 
 
Table 3 Proportion of colorectal adenomas classified as small or large (< or ≥ 10mm) by endoscopic 
and pathology sizing.  
 
 
 
 
Endoscopy 
and 
Pathology 
size <10mm 
Endoscopy 
size <10 mm 
and Pathology 
size ≥10 mm 
Endoscopy 
size ≥10 mm 
and Pathology 
size <10 mm 
Endoscopy 
and 
Pathology 
size ≥10 mm 
 n (%) n (%) n (%) n (%) 
All adenomas 1709 (67.8) 79 (3.1) 106 (4.2) 627 (24.9) 
  Tubular adenoma 1546 (84.3) 48 (2.6) 58   (3.2) 183 (10.0) 
  Tubulovillous adenoma 163   (23.8) 31 (4.5) 48   (7.0) 444 (64.7) 
Restricting to 8-12 mm adenomas* 160   (30.3) 69 (13.1) 80   (15.2) 219 (41.5) 
*According to pathology size 
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Table 4 Factors associated with discordant classification between endoscopic and pathology sizing   
 
 
 
 
Agreed 
Endoscopy and 
Pathology size 
<10 or ≥10mm 
Discordant 
Endoscopy size 
<10mm and 
Pathology size 
≥10mm 
Discordant 
Endoscopy size 
≥10mm and 
Pathology size 
<10mm 
 
 
 
 
 
 n (%) n (%) n (%) P value 
All adenomas 2336 (92.7) 79 (3.1) 106 (4.2)  
BCS endoscopy center     
  A* 
  B* 
361 (89.6) 
440 (92.1) 
10 (2.5) 
25 (5.2) 
32 (7.9) 
13 (2.7) 
 
  C  230 (89.5) 12 (4.7) 15 (5.8)  
  D  505 (95.1) 11 (2.1) 15 (2.8)  
  E 800 (93.9) 21 (2.5) 31 (3.6) <0.001 
Sex     
  Female 653   (92.5) 21 (3.0) 32 (4.5)  
  Male 1683 (92.7) 58 (3.2) 74 (4.1) 0.85 
Topography     
  Right-sided 1823 (92.7) 63 (3.2) 81 (4.1)  
  Left-sided** 505   (92.5) 16 (2.9) 25 (4.6) 0.85 
*Same pathology department services these 2 endoscopy centers. 
**Left-sided:  rectum, rectosigmoid, sigmoid colon, descending colon and splenic flexure. Site was 
unspecified for n=8 adenomas. 
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Table 5 Proportion of individuals stratified into future neoplasia risk and surveillance intervals according to adenoma size and multiplicity. 
 
 
 
 
Agreed  
Endoscopy and 
Pathology size 
<10 mm 
Discordant 
Endoscopy size <10 mm 
and  
Pathology size ≥10 mm 
Discordant  
Endoscopy size ≥10 mm 
and  
Pathology size <10 mm 
Agreed 
Endoscopy and 
Pathology size 
≥10 mm 
Total 
 
 
 
 n (%) n (%) n (%) n (%) n (%) 
All adenoma patients  712 (50.9) 52 (3.7) 83 (5.9) 553 (39.5) 1400 (100) 
Multiplicity 
  1-2 
  3-4 
  ≥5 
 
633 (45.2) 
64   (4.6) 
15   (1.1) 
 
33 (2.4) 
16 (1.1) 
3   (0.2) 
 
66 (4.7) 
12 (0.9) 
5   (0.4) 
 
441 (29.4) 
83    (5.9) 
29    (2.1) 
 
1173 (83.8) 
175    (12.5) 
52      (3.7) 
AGA: multiplicity/HGD/villousness and endoscopy size 
  Low risk 
  High risk 
 
514 (36.7) 
198 (14.1) 
 
18 (1.3) 
34 (2.4) 
 
0   (0.0) 
83 (5.9) 
 
0      (0.0) 
553 (39.5) 
 
532 (38.0) 
868 (62.0) 
AGA: multiplicity/HGD/villousness and pathology size 
  Low risk 
  High risk 
 
514 (36.7) 
198 (14.1) 
 
0   (0.0) 
52 (3.7) 
 
34 (2.4) 
49 (3.5) 
 
0      (0.0) 
553 (39.5) 
 
548 (39.1) 
852 (60.9) 
BSG: multiplicity and endoscopy size  
  Low risk  
  Intermediate risk 
  High risk 
 
633 (45.2) 
64   (4.6) 
15   (1.1) 
 
33 (2.4) 
16 (1.1) 
3   (0.2) 
 
0 
66 (4.7) 
17 (1.2) 
 
0  
441 (29.4) 
112 (8.0) 
 
666    (47.6) 
613    (41.9) 
111    (10.5) 
BSG: multiplicity and pathology size 
  Low risk  
 
633 (45.2) 
 
0  
 
66 (4.7) 
 
0  
 
699    (49.9) 
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  Intermediate risk 
  High risk 
64   (4.6) 
15   (1.1) 
33 (2.4) 
19 (1.3) 
12 (0.9) 
5   (0.4) 
441 (29.4) 
112 (8.0) 
550    (39.3) 
151    (10.8) 
    
All percentages are shown as a % of n=1400 individuals.  AGA: American Gastroenterological Association strata into colonoscopy surveillance, determined by 
adenoma size, multiplicity, villousness and high-grade dysplasia presence.(8)  Low risk (1-2 tubular adenomas, each <10 mm, none with high-grade dysplasia): 
offered 5 to 10 year surveillance; High risk (≥3 adenomas, or at least one villous/tubulovillous adenoma, any adenoma with high-grade dysplasia or any adenoma 
≥10 mm): offered 3-year surveillance.  BSG: British Society of Gastroenterology strata into colonoscopy surveillance, determined by adenoma size and multiplicity.
 5
  
Low risk (1-2 adenomas, each <10 mm): offered 5-year or no surveillance; Medium risk (3-4 adenomas, all <10 mm, or any adenoma ≥10 mm): offered 3-year 
surveillance; High risk (5 or more adenomas of any size, or 3 adenomas with at least 1 ≥10 mm): offered 1 year surveillance.
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ACPGBI: Association of Coloproctology for Great Britain and Ireland 
AGA:  American Gastroenterology Association 
BCS:   Bowel Cancer Screening 
BSG:   British Society of Gastroenterology 
CRC:   Colorectal cancer 
FOB:   Fecal-occult blood 
